Good Question!
I don't know if you viewed my post regarding the side-by-side comparisons of RGBP Vs ENZ*C and the MANY reasons why RGBP should do far better Post-Pink Current, but the rationale is $1+ which is a reasonable assumption based on the following:
RGBP holds 20+ Patents that represent Disruptive Biotechnology and center on mRNA Biotechnology (The Future of Medicine) AND has a licensing deal in place with Oncology Pharma for one of its Patents with (2) FDA Approved INDs for treating pancreatic & colon cancer that is right now in the process of entering clinical trials if it hasn't already.
RGBP's 20+ Patents combined are worth $TRILLIONS "as is" TODAY!!
Why is this relevant??? As a comparison, in 2017 Kite Pharma was bought out by Gilead Sciences for $11.9 BILLION CASH for a single Patent that had not been FDA approved for an IND at that time...and Kite like RGBP is in the Immuno-Oncology space and their only Patent is mRNA based as are many of RGBP's.
Although ENZ*C has a promising future with its one and only Patent that has to do with HIV treatment, it by FAR is no comparison to what RGBP has, not even close. i.e. no active licensing deal therefore no prospect of revenue, no FDA approval for an IND therefore not anywhere near entering clinical trials, no partnership, etc and none of this is a put down to ENZ*C, it's just simply the facts of where they are in development but yet back in Feb this year, 19 days after going Pink Current, their PPS made a run to nearly $1.00.
If RGBP doesn't do much better than $1 soon after Post-Pink Current I'll be very surprised....but as we all know anything can happen on the OTC.
My personal opinion only but one that makes common sense.
Be well and prosper...
